

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name, Degree, Org	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Adam Deising, DO Scripps Clinic	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Robert Gish, MD Robert G. Gish Consultants, LLC	Speaker	<ul style="list-style-type: none"> Gilead Sciences, Inc. 	<ul style="list-style-type: none"> Research Support
		<ul style="list-style-type: none"> Abbott, AbbVie, Altimmune, Antios, Arrowhead, Bristol-Myers Squibb Company, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Venatorx, Viking Therapeutics 	<ul style="list-style-type: none"> Advisor, consultant
		<ul style="list-style-type: none"> Abbott, AbbVie, Antios, Arrowhead, Dova Pharmaceuticals, Eiger, Enyo, Gilead, HepQuant, Intercept, Janssen, Merck, Prodigy 	<ul style="list-style-type: none"> Advisory Boards
		<ul style="list-style-type: none"> Abbvie, Abbot, Access Biological, ADMA Biologic, AEC Partner, Aligos Therapeutic, Arena Pharmaceuticals, Arrowhead, aligos, Atrena, Arterys, Inc, Alexion, Altimune, Antios Therapeutics, AproTX, Bayer, Cirina, Consumer Heath Products, CymaBay Therapeutics, Inc, DiaSorinm, Inc, Dovia Pharma, DRG Abacus, DURECT Corporation, Dynavax, Exhosens, Eiger, Eisai, Enyo, Exelixis, Fibronostics Inc, Forty-Seven Inc, Fujifilm Wako Diagnostics, Gilead Sciences, HepQuant, HepaTx, IDLogiq, Intercept, Inotek, Iqvia, Janssen, KannaLife, Laboratory for Advanced Medicine, Labyrinth Holdings, Life Line Screening, Lilly, MedImmune, Merck, New Enterprise Associates, Ogilvy CommonHealth, Patient Connect Perspectum, Pfizer, Pharmaceutical Research 	<ul style="list-style-type: none"> Consultant

		Associates, ProdigY Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shenzhen HEC Industrial Development, Shionogi Inc, Tonghua Anrate Biopharmaceutical, Topography Health, Trimaran, Venatorx	
		<ul style="list-style-type: none"> • Biocollections, Fibronostics, Fujifilm/Wako, Perspectum, Quest, Sonic Incytes 	<ul style="list-style-type: none"> • Consultant
		<ul style="list-style-type: none"> • Altimune, Arrowhead, CymaBay Therapeutics, Durect 	<ul style="list-style-type: none"> • Data Safety Monitoring Board
		<ul style="list-style-type: none"> • Topography Health 	<ul style="list-style-type: none"> • Research
		<ul style="list-style-type: none"> • AbbVie, BMS, Eisai, Gilead • Sciences Inc., Intercept 	<ul style="list-style-type: none"> • Speaker
		<ul style="list-style-type: none"> • RiboSciences, CoCrystal 	<ul style="list-style-type: none"> • Minor stock shareholder
		<ul style="list-style-type: none"> • Genlantis, HepQuant, AngioCrine 	<ul style="list-style-type: none"> • Stock Options
Julio Gutierrez, MD Scripps MD Anderson Cancer Center	Course Director, Speaker	<ul style="list-style-type: none"> • Durect Corporation 	<ul style="list-style-type: none"> • Research funding
		<ul style="list-style-type: none"> • AbbVie, Alexion, Gilead Sciences, Inc, Exelixis, Intercept Pharmaceuticals 	<ul style="list-style-type: none"> • Speaker, Advisory Board
		<ul style="list-style-type: none"> • ProSciento 	<ul style="list-style-type: none"> • Researcher
		<ul style="list-style-type: none"> • Merck, Metacrine, Regeneron 	<ul style="list-style-type: none"> • Principle Investigator
Kris Kowdley, MD Liver Institute Northwest	Speaker	<ul style="list-style-type: none"> • Gilead, HighTide, Mirum, Pliant; Genfit, CymaBay, GSK, Viking, Pfizer, Intercept, NGM Bio, 89Bio, Celgene, BMS, Corcept, Metacrine, Hanmi, Terns, Madrigal, Enanta, Protagonist 	<ul style="list-style-type: none"> • Research Support, Consultant
		<ul style="list-style-type: none"> • Abbvie; Gilead; Intercept 	<ul style="list-style-type: none"> • Speaker's Bureau
		<ul style="list-style-type: none"> • Gilead, Intercept, HighTide, Mirum, Genfit, CymaBay; Inipharm, Madrigal, NGM, 89Bio, Pfizer, Enanta 	<ul style="list-style-type: none"> • Advisory Board
		<ul style="list-style-type: none"> • Inipharm 	<ul style="list-style-type: none"> • Stock Ownership
Rohit Loombay, MD UC San Diego	Speaker	<ul style="list-style-type: none"> • AbbVie Gilead Sciences, Inc, Genfit, Merck 	<ul style="list-style-type: none"> • Research Funding
Paul Pockros, MD Scripps Clinic	Course Director, Moderator, Speaker	<ul style="list-style-type: none"> • AbbVie, Intercept Pharmaceuticals 	<ul style="list-style-type: none"> • Speakers Bureau, Advisory Board
		<ul style="list-style-type: none"> • AbbVie, Bayer, Gilead Sciences, Inc, Intercept Pharmaceuticals 	<ul style="list-style-type: none"> • Unrestricted CME funds to University of Louisville/SC Liver Research Consortium
Michael Schilsky, MD Yale School of Medicine	Speaker	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Amit Singal, MD	Speaker	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • None

University of Texas Southwestern			
Florence Wong, MD University of Toronto	Speaker	<ul style="list-style-type: none"> Mallinckrodt Pharmaceutical, Sequana Medical 	<ul style="list-style-type: none"> Research Grant - Paid to Institution
		<ul style="list-style-type: none"> Ocelot Bio, River 2 Renal Corporation 	<ul style="list-style-type: none"> Consultant
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.